The upregulation of the mTOR and AKT was also demonstrated in NSCLC with up to 90% of phosphorylated mTOR (p-mTOR) in 90% of patients with adenocarcinoma, 60% of patients with large cell carcinoma, and 40% of patients with squamous cell carcinoma [75,76]. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.